Upgrade to SI Premium - Free Trial

Form SCHEDULE 13D/A Fresenius Medical Care Filed by: Fresenius SE & Co. KGaA

August 24, 2026 4:10 PM





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
According to Fresenius Medical Care AG's Annual Report on Form 20-F for the year ended December 31, 2025, American Depositary Shares ("ADSs") representing its ordinary shares without par value are listed on the New York Stock Exchange and registered under Section 12 of the Securities Exchange Act of 1934, and its ordinary shares are so listed and registered solely in connection with the listing and registration of such ADSs. The CUSIP number set forth on the cover of this Schedule 13D is the CUSIP number assigned to the ADSs.


SCHEDULE 13D


Fresenius SE & Co. KGaA
Signature:/s/ Sara Hennicken
Name/Title:Sara Hennicken/Member of the Management Board and Chief Financial Officer
Date:08/24/2026
Signature:/s/ Thomas Neidert
Name/Title:Thomas Neidert/Authorized Signatory
Date:08/24/2026

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

EXHIBIT 99.2

EXHIBIT 99.3

Categories

SEC Filings